Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Orphenadrine citrate
Drug ID BADD_D01626
Description A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Indications and Usage Indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB01173
KEGG ID D00774
MeSH ID D009966
PubChem ID 83823
TTD Drug ID D0D9FV
NDC Product Code 50090-0169; 71335-0117; 22568-1022; 53002-5430; 61919-177; 80425-0117; 51927-0127; 17478-538; 63629-1564; 49452-4936; 51927-0245; 43386-480; 67296-0709; 46016-0140; 0185-0022; 0591-3222; 80425-0340; 67763-119; 43063-407; 63187-122; 63187-632; 68788-9138; 70934-952; 0115-2011; 60760-810; 51927-0006; 51552-1353; 71554-012; 49999-046; 72162-2020; 0641-6182; 38779-0452
UNII X0A40N8I4S
Synonyms Orphenadrine | Methyldiphenylhydramine | Lysantin | Mefenamine | Mephenamine | Norflex | Orphenadrine Citrate | Citrate, Orphenadrine | Orphenadrine Hydrochloride | Hydrochloride, Orphenadrine | Sodium Mefenamine | Mefenamine, Sodium | Disipal | Norflex Orphenadrine Citrate | Citrate, Norflex Orphenadrine | Orphenadrine Citrate, Norflex
Chemical Information
Molecular Formula C24H31NO8
CAS Registry Number 4682-36-4
SMILES CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Asthenia08.01.01.001--Not Available
Constipation07.02.02.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry skin23.03.03.001--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Intraocular pressure increased13.07.04.002--Not Available
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nausea07.01.07.001--
Palpitations02.11.04.012--
Pruritus23.03.12.001--
Somnolence19.02.05.003; 17.02.04.006--
Tachycardia02.03.02.007--Not Available
Tremor17.01.06.002--
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Epigastric discomfort07.01.02.004--Not Available
The 1th Page    1    Total 1 Pages